SCHEMBL2228203

SCHEMBL2228203

Cc1ccc(C(=O)O)cc1Nc1nccc(-c2cn(C(C)C)c3cnccc23)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.47
MKNK2 Q9HBH9 1/20 0.47
ABL1 P00519 10/20 0.44
PDGFRA P16234 9/20 0.44
PDGFRB P09619 8/20 0.44
BCR P11274 7/20 0.44
EGFR P00533 3/20 0.44
PRKCA P17252 2/20 0.44
KIT P10721 3/20 0.43
CAMKK2 Q96RR4 1/20 0.43
LCK P06239 2/20 0.42
LYN P07948 2/20 0.42
FLT3 P36888 2/20 0.42
DDR2 Q16832 2/20 0.42
CCND1 P24385 1/20 0.42
CDK6 Q00534 1/20 0.42
DYRK1A Q13627 2/20 0.42
GSK3B P49841 2/20 0.42
NFATC1 O95644 1/20 0.42
CDK2 P24941 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2227980 0.92 CAMKK2 (0.49) MKNK1MKNK2ABL1PDGFRAPDGFRB
SCHEMBL2352742 0.91 MKNK1 (0.49) MKNK1MKNK2ABL1PDGFRAPDGFRB
SCHEMBL2227712 0.89 MKNK1 (0.55) MKNK1MKNK2ABL1BCREGFR
SCHEMBL2227237 0.86 ABL1 (0.57) MKNK1MKNK2ABL1PDGFRAPDGFRB
SCHEMBL2230113 0.85 MKNK1 (0.50) MKNK1MKNK2ABL1BCREGFR
SCHEMBL2227747 0.83 MKNK1 (0.48) MKNK1MKNK2EGFRCAMKK2LCK
SCHEMBL2229746 0.83 MKNK2 (0.55) MKNK1MKNK2ABL1BCRPRKCA
SCHEMBL2229446 0.83 MKNK1 (0.47) MKNK1MKNK2ABL1PDGFRAPDGFRB
SCHEMBL2229567 0.82 CAMK2D (0.43) MKNK1MKNK2ABL1BCREGFR
SCHEMBL2230864 0.82 MKNK1 (0.43) MKNK1MKNK2ABL1BCREGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183975-A1 NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY GOTO YASUHIRO 2011-07-28 US disclosed
US-20110183975-A1 NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY GOTO YASUHIRO 2011-07-28 US disclosed
US-20110183975-A1 NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY GOTO YASUHIRO 2011-07-28 US disclosed
WO-2010042337-A1 NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY MERCK SHARP & DOHME CORP. (US) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183975-A1 NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY BRIX1, REL, CNKSR1 MKNK1 332/4885MKNK2 181/4885ABL1 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.